Evidence map›Paper›PMID 27294018›Full record

ArticleApplied & translational genomics2014

Simultaneous genomic identification and profiling of a single cell using semiconductor-based next generation sequencing.

Manabu Watanabe, Junko Kusano, Shinsaku Ohtaki, Takashi Ishikura, Jin Katayama, Akira Koguchi, Michael Paumen, Yoshiharu Hayashi

Abstract read
In one paragraph

Article in Applied & translational genomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Manabu WatanabeLife Technologies Japan Ltd., a part of Thermo Fisher Scientific. 4-2-8 Shibaura, Minato-ku Tokyo 108-0023, Japan.
Junko KusanoLife Technologies Japan Ltd., a part of Thermo Fisher Scientific. 4-2-8 Shibaura, Minato-ku Tokyo 108-0023, Japan.
Shinsaku OhtakiLife Technologies Japan Ltd., a part of Thermo Fisher Scientific. 4-2-8 Shibaura, Minato-ku Tokyo 108-0023, Japan.
Takashi IshikuraLife Technologies Japan Ltd., a part of Thermo Fisher Scientific. 4-2-8 Shibaura, Minato-ku Tokyo 108-0023, Japan.
Jin KatayamaLife Technologies Japan Ltd., a part of Thermo Fisher Scientific. 4-2-8 Shibaura, Minato-ku Tokyo 108-0023, Japan.
Akira KoguchiLife Technologies Japan Ltd., a part of Thermo Fisher Scientific. 4-2-8 Shibaura, Minato-ku Tokyo 108-0023, Japan.
Michael PaumenLife Technologies Japan Ltd., a part of Thermo Fisher Scientific. 4-2-8 Shibaura, Minato-ku Tokyo 108-0023, Japan.
Yoshiharu HayashiLife Technologies Japan Ltd., a part of Thermo Fisher Scientific. 4-2-8 Shibaura, Minato-ku Tokyo 108-0023, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combining single-cell methods and next-generation sequencing should provide a powerful means to understand single-cell biology and obviate the effects of sample heterogeneity. Here we report a single-cell identification method and seamless cancer gene profiling using semiconductor-based massively parallel sequencing. A549 cells (adenocarcinomic human alveolar basal epithelial cell line) were used as a model. Single-cell capture was performed using laser capture microdissection (LCM) with an Arcturus® XT system, and a captured single cell and a bulk population of A549 cells (≈ 10(6) cells) were subjected to whole genome amplification (WGA). For cell identification, a multiplex PCR method (AmpliSeq™ SNP HID panel) was used to enrich 136 highly discriminatory SNPs with a genotype concordance probability of 10(31-35). For cancer gene profiling, we used mutation profiling that was performed in parallel using a hotspot panel for 50 cancer-related genes. Sequencing was performed using a semiconductor-based bench top sequencer. The distribution of sequence reads for both HID and Cancer panel amplicons was consistent across these samples. For the bulk population of cells, the percentages of sequence covered at coverage of more than 100 × were 99.04% for the HID panel and 98.83% for the Cancer panel, while for the single cell percentages of sequence covered at coverage of more than 100 × were 55.93% for the HID panel and 65.96% for the Cancer panel. Partial amplification failure or randomly distributed non-amplified regions across samples from single cells during the WGA procedures or random allele drop out probably caused these differences. However, comparative analyses showed that this method successfully discriminated a single A549 cancer cell from a bulk population of A549 cells. Thus, our approach provides a powerful means to overcome tumor sample heterogeneity when searching for somatic mutations.

Indexed as

HeterogeneityLaser capture microdissectionSemiconductor-based sequencingSingle cell identification

Identifiers

PMID27294018
PMCPMC4887956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.